RU2004102500A - Композиции интерферонов - Google Patents
Композиции интерферонов Download PDFInfo
- Publication number
- RU2004102500A RU2004102500A RU2004102500/15A RU2004102500A RU2004102500A RU 2004102500 A RU2004102500 A RU 2004102500A RU 2004102500/15 A RU2004102500/15 A RU 2004102500/15A RU 2004102500 A RU2004102500 A RU 2004102500A RU 2004102500 A RU2004102500 A RU 2004102500A
- Authority
- RU
- Russia
- Prior art keywords
- composition according
- interferon
- polypeptide
- composition
- amino acid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 55
- 102000014150 Interferons Human genes 0.000 title claims 21
- 108010050904 Interferons Proteins 0.000 title claims 21
- 229940079322 interferon Drugs 0.000 title claims 2
- 102220519361 Coatomer subunit alpha_C17S_mutation Human genes 0.000 claims 20
- 102220067563 rs200327756 Human genes 0.000 claims 14
- 102220603130 Transcription factor SOX-4_K45R_mutation Human genes 0.000 claims 12
- 102000008070 Interferon-gamma Human genes 0.000 claims 8
- 108010074328 Interferon-gamma Proteins 0.000 claims 8
- 102000003996 Interferon-beta Human genes 0.000 claims 7
- 108090000467 Interferon-beta Proteins 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 7
- 229920000858 Cyclodextrin Polymers 0.000 claims 5
- 102220480985 Nicotinate phosphoribosyltransferase_Q51N_mutation Human genes 0.000 claims 5
- 102220580583 NEDD4-binding protein 2-like 1_K33R_mutation Human genes 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 102220476665 Dynein axonemal assembly factor 10_S75T_mutation Human genes 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 3
- 239000006172 buffering agent Substances 0.000 claims 3
- 229940044627 gamma-interferon Drugs 0.000 claims 3
- 230000013595 glycosylation Effects 0.000 claims 3
- 238000006206 glycosylation reaction Methods 0.000 claims 3
- 229960001388 interferon-beta Drugs 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 3
- -1 sulfoalkyl ether cyclodextrin derivative Chemical class 0.000 claims 3
- 125000004964 sulfoalkyl group Chemical group 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 102220466793 HLA class II histocompatibility antigen, DR beta 5 chain_L28S_mutation Human genes 0.000 claims 2
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000006193 liquid solution Substances 0.000 claims 2
- 239000002736 nonionic surfactant Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 239000003755 preservative agent Substances 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102220104696 rs879253900 Human genes 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 102220491096 ADP-ribosylation factor 6_H97N_mutation Human genes 0.000 claims 1
- 102220627590 Coagulation factor IX_K45N_mutation Human genes 0.000 claims 1
- 102220627589 Coagulation factor IX_L20S_mutation Human genes 0.000 claims 1
- 102220576032 HLA class I histocompatibility antigen, B alpha chain_Q94S_mutation Human genes 0.000 claims 1
- 102220541980 HLA class II histocompatibility antigen, DQ beta 1 chain_Y92N_mutation Human genes 0.000 claims 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 claims 1
- 102220548011 Inducible T-cell costimulator_Q10S_mutation Human genes 0.000 claims 1
- 101710147309 Interferon epsilon Proteins 0.000 claims 1
- 102100026688 Interferon epsilon Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 102220520996 N-chimaerin_D54T_mutation Human genes 0.000 claims 1
- 230000004988 N-glycosylation Effects 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 102220553025 Proenkephalin-A_D39S_mutation Human genes 0.000 claims 1
- 102220516730 Protease-associated domain-containing protein 1_L21S_mutation Human genes 0.000 claims 1
- 102220547369 Protein APCDD1_L65S_mutation Human genes 0.000 claims 1
- 102220486979 Sodium-dependent phosphate transport protein 1_S76N_mutation Human genes 0.000 claims 1
- 102220577394 Stromal cell-derived factor 1_K45S_mutation Human genes 0.000 claims 1
- 102220566198 Survival motor neuron protein_F70S_mutation Human genes 0.000 claims 1
- 102220603542 TYRO protein tyrosine kinase-binding protein_R27N_mutation Human genes 0.000 claims 1
- 102220603146 Transcription factor SOX-4_I59S_mutation Human genes 0.000 claims 1
- 102220472118 Transmembrane protein_Q48N_mutation Human genes 0.000 claims 1
- 102220487674 Uridine diphosphate glucose pyrophosphatase NUDT22_K19N_mutation Human genes 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 239000007900 aqueous suspension Substances 0.000 claims 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 1
- 229960004853 betadex Drugs 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 102200094703 c.232G>A Human genes 0.000 claims 1
- 102220354160 c.245C>A Human genes 0.000 claims 1
- 102220360521 c.295T>A Human genes 0.000 claims 1
- 102220389089 c.33G>T Human genes 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 238000002144 chemical decomposition reaction Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 102000043557 human IFNG Human genes 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 108010045648 interferon omega 1 Proteins 0.000 claims 1
- 108700027921 interferon tau Proteins 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000000644 isotonic solution Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229940071643 prefilled syringe Drugs 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 102220224485 rs1060502686 Human genes 0.000 claims 1
- 102220236328 rs1131691720 Human genes 0.000 claims 1
- 102220085575 rs140584714 Human genes 0.000 claims 1
- 102220244835 rs1554042187 Human genes 0.000 claims 1
- 102220039277 rs199473352 Human genes 0.000 claims 1
- 102220268018 rs201210997 Human genes 0.000 claims 1
- 102200037714 rs2655655 Human genes 0.000 claims 1
- 102200105133 rs28929768 Human genes 0.000 claims 1
- 102200118184 rs33924775 Human genes 0.000 claims 1
- 102220020523 rs397508412 Human genes 0.000 claims 1
- 102200080720 rs4077515 Human genes 0.000 claims 1
- 102220014798 rs56204273 Human genes 0.000 claims 1
- 102220035775 rs587779734 Human genes 0.000 claims 1
- 102200027869 rs62517167 Human genes 0.000 claims 1
- 102200087964 rs63751258 Human genes 0.000 claims 1
- 102200021380 rs727504457 Human genes 0.000 claims 1
- 102220232854 rs766277488 Human genes 0.000 claims 1
- 102220312163 rs772475317 Human genes 0.000 claims 1
- 102220018673 rs80358415 Human genes 0.000 claims 1
- 102220137564 rs886055455 Human genes 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 239000008247 solid mixture Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Virology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200101040 | 2001-06-29 | ||
| DKPA200101040 | 2001-06-29 | ||
| DKPA200101277 | 2001-08-30 | ||
| DKPA200101277 | 2001-08-30 | ||
| DKPA200200257 | 2002-02-19 | ||
| DKPA200200257 | 2002-02-19 | ||
| PCT/DK2002/000444 WO2003002152A2 (en) | 2001-06-29 | 2002-06-28 | Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2004102500A true RU2004102500A (ru) | 2005-04-10 |
Family
ID=27222516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004102500/15A RU2004102500A (ru) | 2001-06-29 | 2002-06-28 | Композиции интерферонов |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1414498A2 (https=) |
| JP (1) | JP2004522803A (https=) |
| CN (1) | CN1522159A (https=) |
| CA (1) | CA2452364A1 (https=) |
| MX (1) | MXPA03011793A (https=) |
| RU (1) | RU2004102500A (https=) |
| WO (1) | WO2003002152A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2482871C2 (ru) * | 2010-06-07 | 2013-05-27 | Общество с ограниченной ответственностью "Центр Инновационных Технологий "БиоФарм" (ООО "ЦИТ "БиоФарм") | Композиция для лечения вирусных заболеваний животных |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7959910B2 (en) | 2000-07-31 | 2011-06-14 | Biolex Therapeutics, Inc. | C-terminally truncated interferon alpha variants |
| AU2003254641A1 (en) * | 2002-08-28 | 2004-03-19 | Maxygen Aps | Interferon beta-like molecules for treatment of cancer |
| US20040126360A1 (en) * | 2002-10-09 | 2004-07-01 | Manning Mark C. | Oral formulations for proteins and polypeptides |
| JP5207590B2 (ja) | 2002-12-26 | 2013-06-12 | マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド | 増強された生物学的能力を有するインターフェロン−βのポリマー結合体 |
| CA2547822A1 (en) * | 2003-12-11 | 2005-06-30 | Ares Trading S.A. | Stabilized interferon liquid formulations |
| CA2567309A1 (en) | 2004-06-01 | 2005-12-15 | Ares Trading S.A. | Method of stabilizing proteins |
| CN1984674A (zh) * | 2004-06-07 | 2007-06-20 | 纳斯泰克制药公司 | 不含蛋白质或多肽类稳定剂的干扰素β鼻内制剂 |
| US20060024272A1 (en) * | 2004-07-29 | 2006-02-02 | Large Scale Biology Corporation | C-terminally truncated interferon |
| WO2007022799A1 (en) * | 2005-08-26 | 2007-03-01 | Ares Trading S.A. | Process for the preparation of glycosylated interferon beta |
| US20070243163A1 (en) * | 2006-02-17 | 2007-10-18 | Chih-Ping Liu | Respiratory tract delivery of interferon-tau |
| EP1991679A2 (fr) * | 2006-03-08 | 2008-11-19 | Biomethodes | Variants de l'interferon- gamma humain (ifngamma) |
| JP2008069073A (ja) * | 2006-09-12 | 2008-03-27 | Yokohama Tlo Co Ltd | ラクトフェリン複合体及びその製造方法 |
| WO2008076933A2 (en) * | 2006-12-14 | 2008-06-26 | Bolder Biotechnology, Inc. | Long acting proteins and peptides and methods of making and using the same |
| JP5681485B2 (ja) | 2007-04-27 | 2015-03-11 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | クロピドグレルおよびスルホアルキルエーテルシクロデキストリンを含有する製剤ならびに使用方法 |
| US7625555B2 (en) | 2007-06-18 | 2009-12-01 | Novagen Holding Corporation | Recombinant human interferon-like proteins |
| JP5563475B2 (ja) | 2007-12-20 | 2014-07-30 | メルク セローノ ソシエテ アノニム | Ｐｅｇインターフェロン−ベータ製剤 |
| US10463677B2 (en) | 2008-11-07 | 2019-11-05 | Cydex Pharmaceuticals, Inc. | Composition containing sulfoalkyl ether cyclodextrin and latanoprost |
| MX2011005051A (es) * | 2008-11-17 | 2011-06-01 | Genentech Inc | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas. |
| CA2761455C (en) | 2009-05-13 | 2018-06-12 | Cydex Pharmaceuticals, Inc. | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| DE202012012955U1 (de) | 2011-10-21 | 2014-07-14 | Abbvie Inc. | Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV |
| EP2583677A3 (en) | 2011-10-21 | 2013-07-03 | Abbvie Inc. | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon. |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US10344204B2 (en) | 2015-04-09 | 2019-07-09 | Diversion Technologies, LLC | Gas diverter for well and reservoir stimulation |
| US10012064B2 (en) | 2015-04-09 | 2018-07-03 | Highlands Natural Resources, Plc | Gas diverter for well and reservoir stimulation |
| CN115400220A (zh) | 2015-12-30 | 2022-11-29 | 豪夫迈·罗氏有限公司 | 减少聚山梨酯降解的制剂 |
| US10982520B2 (en) | 2016-04-27 | 2021-04-20 | Highland Natural Resources, PLC | Gas diverter for well and reservoir stimulation |
| EA201892448A1 (ru) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения |
| WO2017194783A1 (en) * | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Targeted mutant interferon-beta and uses thereof |
| WO2020028275A1 (en) * | 2018-07-30 | 2020-02-06 | The Board Of Trustees Of The Leland Stanford Junior University | Interferon-gamma biased agonists |
| CN111358938B (zh) * | 2020-03-30 | 2023-08-11 | 温州肯恩大学(Wenzhou-KeanUniversity) | 人干扰素-ε与干扰素-γ组合药及用途 |
| CN113797317B (zh) * | 2021-10-26 | 2024-01-09 | 科兴生物制药股份有限公司 | 一种组合物及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5997856A (en) * | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
| US5376645A (en) * | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US6046177A (en) * | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| US6133248A (en) * | 1997-06-13 | 2000-10-17 | Cydex, Inc. | Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof |
-
2002
- 2002-06-28 MX MXPA03011793A patent/MXPA03011793A/es unknown
- 2002-06-28 JP JP2003508390A patent/JP2004522803A/ja not_active Withdrawn
- 2002-06-28 CA CA002452364A patent/CA2452364A1/en not_active Abandoned
- 2002-06-28 RU RU2004102500/15A patent/RU2004102500A/ru not_active Application Discontinuation
- 2002-06-28 EP EP02748632A patent/EP1414498A2/en not_active Withdrawn
- 2002-06-28 WO PCT/DK2002/000444 patent/WO2003002152A2/en not_active Ceased
- 2002-06-28 CN CNA028131215A patent/CN1522159A/zh active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2482871C2 (ru) * | 2010-06-07 | 2013-05-27 | Общество с ограниченной ответственностью "Центр Инновационных Технологий "БиоФарм" (ООО "ЦИТ "БиоФарм") | Композиция для лечения вирусных заболеваний животных |
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA03011793A (es) | 2004-04-02 |
| CA2452364A1 (en) | 2003-01-09 |
| CN1522159A (zh) | 2004-08-18 |
| JP2004522803A (ja) | 2004-07-29 |
| WO2003002152A3 (en) | 2003-05-01 |
| WO2003002152A2 (en) | 2003-01-09 |
| EP1414498A2 (en) | 2004-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2004102500A (ru) | Композиции интерферонов | |
| EP2586459B1 (en) | Vegf antagonist formulations | |
| EP1417972B1 (en) | Stabilized teriparatide solutions | |
| JP5026567B2 (ja) | インスリン組成物および組成物の製造方法 | |
| US5597802A (en) | Method of formulating IGF-I with growth hormone | |
| RU2002133236A (ru) | Новая фармацевтическая композиция | |
| EA012205B1 (ru) | Гидрогелевые препараты интерферона | |
| CA2545034A1 (en) | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices | |
| TW201408337A (zh) | 長效胰促泌素肽接合物之液體製劑 | |
| EP3056211A1 (en) | Freeze-dried formulations of fgf-18 | |
| JP4255515B2 (ja) | 安定化された成長ホルモン処方物およびその製造方法 | |
| US20200222508A1 (en) | Glucagon-like peptide 1 (glp-1) receptor agonist compositions | |
| JP4988562B2 (ja) | 安定化したインターフェロン液体製剤 | |
| RU2413528C2 (ru) | Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения | |
| EP1641486B1 (en) | Stable, aqueous solution of human erythropoietin, not containing serum albumin | |
| KR101149454B1 (ko) | 생리활성 펩티드의 액상 제제 | |
| JP2015535238A (ja) | ペグインターフェロンα−２ｂの安定な医薬組成物 | |
| KR20160048227A (ko) | 고나도트로핀을 위한 제제 | |
| US20220152155A1 (en) | Formulations for bovine granulocyte colony stimulating factor and variants thereof | |
| US20170360891A1 (en) | Stable, Benzyl Alcohol-free Aqueous Solution Formulations Containing Alpha-type Interferon | |
| EP3125922A1 (en) | Liquid pharmaceutical composition of conjugated erythropoietin | |
| WO2022197963A1 (en) | Long-acting growth hormone compositions | |
| MXPA06013308A (es) | Formulaciones de hidrogel que contienen interferon. | |
| HK1061521A1 (en) | Insulin preparations, which do not contain any zinc or only a small quantity of zinc and which have an improved stability | |
| HK1184680B (en) | Vegf antagonist formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20060210 |